Diabetic nephropathy in 2014: Improved cardiorenal prognosis in diabetic nephropathy

Nature Reviews Nephrology

Volumn 11, Issue 2, 2015, Pages 68-70

  Parving, Hans Henrik ^a   Rossing, Peter ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b STENO DIABETES CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATRASENTAN; BARDOXOLONE METHYL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; LIPID; ENDOTHELIN RECEPTOR ANTAGONIST; PYRROLIDINE DERIVATIVE;

ALBUMINURIA; BLOOD PRESSURE REGULATION; CARDIORENAL SYNDROME; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; MACROALBUMINURIA; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY EXCRETION; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETIC NEPHROPATHIES;

CARDIOVASCULAR DISEASES; DIABETIC NEPHROPATHIES; ENDOTHELIN RECEPTOR ANTAGONISTS; HUMANS; PROGNOSIS; PYRROLIDINES;

EID: 84961330019     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2014.238     Document Type: Review

References (10)

1. de Zeeuw, D. et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110, 921-927 (2004).
2. Schmieder, R. E. et al. Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies. Diabetologia 57, 2019-2029 (2014).
3. Andresdottir, G. et al. Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors. Diabetes Care 37, 1660-1667 (2014).
4. Gaede, P., Lund-Andersen, H., Parving, H.-H. & Pedersen, O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358, 580-591 (2008).
5. Gregg, E. W. et al. Changes in diabetes-related complications in the United States, 1990-2010. N. Engl. J. Med. 370, 1514-1523 (2014).
6. de Zeeuw, D. et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 25, 1083-1093 (2014).
7. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01858532 (2014).
8. Pergola, P. E. et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327-336 (2011).
9. de Zeeuw, D. et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 369, 2492-2503 (2013).
10. McMurray, J. J., Gerstein, H. C., Holman, R. R. & Pfeffer, M. A. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2, 843-851 (2014).